- American City Business Journals•11 months ago
Research Triangle Park drug developer Envisia Therapeutics reported positive results for a possible next-generation glaucoma treatment. Glaucoma is the leading cause of preventable blindness globally. As with treatments across all diseases, compliance with the drug regiment contributes to poor performing treatments.
We're sorry this is all we were able to find about this topic.
NYSE - NYSE Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|